cisplatin + cyclophosphamide + docetaxel + doxorubicin + etoposide

This is a multi-agent chemotherapy regimen composed of five cytotoxic drugs: cisplatin, cyclophosphamide, docetaxel, doxorubicin, and etoposide. Each component has a distinct mechanism of action targeting rapidly dividing cancer cells through different pathways: - **Cisplatin** is a platinum-based compound that forms DNA crosslinks and inhibits DNA synthesis and function. - **Cyclophosphamide** is an alkylating agent that interferes with DNA replication by forming covalent bonds with DNA. - **Docetaxel** is a taxane that stabilizes microtubules and prevents their depolymerization, inhibiting cell division. - **Doxorubicin** is an anthracycline antibiotic that intercalates into DNA, inhibits topoisomerase II, and generates free radicals leading to cytotoxicity. - **Etoposide** inhibits topoisomerase II activity resulting in double-strand breaks in DNA. This combination aims to maximize antitumor efficacy by attacking cancer cells at multiple points in the cell cycle. Such regimens are typically used for aggressive or refractory cancers where single-agent therapy may be insufficient. The combination increases the risk of severe toxicities including myelosuppression (leukopenia/thrombocytopenia), nephrotoxicity (cisplatin), cardiotoxicity (doxorubicin), neuropathy (cisplatin/docetaxel), mucositis, nausea/vomiting, alopecia, and others[1][2]. This specific five-drug combination does not have a unique brand name but represents an intensive investigational approach sometimes used in clinical trials for high-risk or relapsed malignancies.